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Abstract
Introduction: Vitamin D deficiency is encountered frequently in critically ill patients and might be harmful. Current
nutrition guidelines recommend very low vitamin D doses. The objective of this trial was to evaluate the safety and efficacy
of a single oral high-dose vitamin D3 supplementation in an intensive care setting over a one-week observation period.
Methods: This was a randomized, double-blind, placebo-controlled pilot study in a medical ICU at a tertiary
care university center in Graz, Austria. Twenty-five patients (mean age 62 ± 16yrs) with vitamin D deficiency
[25-hydroxyvitamin D (25(OH)D) ≤20 ng/ml] and an expected stay in the ICU >48 hours were included and
randomly received either 540,000 IU (corresponding to 13.5 mg) of cholecalciferol (VITD) dissolved in 45 ml herbal
oil or matched placebo (PBO) orally or via feeding tube.
Results: The mean serum 25(OH)D increase in the intervention group was 25 ng/ml (range 1-47 ng/ml). The
highest 25(OH)D level reached was 64 ng/ml, while two patients showed a small (7 ng/ml) or no response (1 ng/
ml). Hypercalcemia or hypercalciuria did not occur in any patient. From day 0 to day 7, total serum calcium levels
increased by 0.10 (PBO) and 0.15 mmol/L (VITD; P < 0.05 for both), while ionized calcium levels increased by 0.11
(PBO) and 0.05 mmol/L (VITD; P < 0.05 for both). Parathyroid hormone levels decreased by 19 and 28 pg/ml (PBO
and VITD, ns) over the seven days, while 1,25(OH)D showed a transient significant increase in the VITD group only.
Conclusions: This pilot study shows that a single oral ultra-high dose of cholecalciferol corrects vitamin D
deficiency within 2 days in most patients without causing adverse effects like hypercalcemia or hypercalciuria.
Further research is needed to confirm our results and establish whether vitamin D supplementation can affect the
clinical outcome of vitamin D deficient critically ill patients.
EudraCT Number: 2009-012080-34
German Clinical Trials Register (DRKS): DRKS00000750
Introduction
Hypocalcemia occurs frequently in patients with critical
illness and has been related to adverse clinical outcomes
including increased mortality [1-3]. Underlying reasons
remain largely unknown but vitamin D deficiency and
accompanying secondary hyperparathyroidism may be
one of them. However, there is currently no proven
intervention that corrects and sustains calcium levels
safely and effectively in critical illness. Various forms of
calcium and calcitriol supplementation were unable to
demonstrate sustained effects and in some cases resulted
in hypercalcemia and increased mortality [2]. Several
case reports have suggested vitamin D deficiency as a
cause of hypocalcemia with adverse outcome, which
can be corrected effectively and safely by vitamin D
supplementation [4,5].
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suggest that most critically ill patients are vitamin D
deficient, although there are concerns in this special
group of patients that acute fluid shifts and inflamma-
tory states may influence the assessment and inter-
pretation of vitamin status [10-13]. There is now
extensive literature on adverse health outcomes in
patients with vitamin D deficiency reporting increased
mortality, cardiovascular events and impaired function
of the immune and musculoskeletal systems [14,15].
Many tissues, including cardiomyocytes and immune
cells have a nuclear vitamin D receptor and respond to
1,25-dihydroxyvitamin D (1,25(OH)2D) [16,17]. This
active form of vitamin D is either derived from the
kidney where it is secreted into the circulation or is
formed within the target cell by hydroxylation of 25-
hydroxyvitamin D (25(OH)D) to 1,25(OH)2D. A large
potential for beneficial clinical effects of a normalized
vitamin D status in the setting of critically ill patients
has recently been brought forward and attracted atten-
tion [18]. The beneficial effects of vitamin D on mus-
cle, heart and immune function could be of particular
interest in critical care, especially in patients with
respiratory failure or those who are on mechanical
ventilation for other reasons.
The current recommendation for parenteral vitamin
D3 is 200 IU per day [19], a dose that is too low to have
an effect on serum vitamin D levels in patients with
established vitamin D deficiency. European Society for
ClinicalNutrition and Metabolism (ESPEN) guidelines
do not specifically address vitamin D supplementation
[20,21].
Uncertainty exists on the dosage of vitamin D supple-
mentation that should be used. Vitamin D intoxication
can potentially be life-threatening but the majority of
officially recorded cases could be related to prolonged
intakes of more than 40,000 IU per day [22]. Two study
groups have recently shown safety and efficacy of a sin-
gle high-dose cholecalciferol administration in rheuma-
tologic and elderly patients [23,24], and mean increases
of 26 ng/ml at a dose of 300,000 IU [24] and 28 ng/ml
at 500,000 IU [23] one to three months after administra-
tion were reported. The feasibility of 60,000 IU cholecal-
ciferol given twice a week to critically ill patients has
been studied by a Spanish group but in this report safety
issues were not addressed [25]. Except for dosing pro-
blems, further main limitations of vitamin D administra-
tion include the contraindication for intramuscular
injections in most ICU patients, the unavailability of
parenteral high-dose vitamin D formulations and finally
unreliable gastrointestinal absorption after oral dosing
due to multifactorial gastrointestinal dysfunction,
changes in gastrointestinal blood supply and motility, as
well as the presence of sepsis and multiorgan failure.
Our hypothesis was that a single ultra-high dose may
overcome some of these limitations and is able to
restore normal 25(OH)D levels without causing adverse
effects. The results obtained from this study should pro-
vide a basis of an easy-to-administer dosing regimen for
other prospective intervention trials in an ICU setting.
Materials and methods
The trial was started in August 2009 and terminated in
January 2010. In a single-center setting of a tertiary care
university hospital, 25(OH)D-deficient adult patients
(levels ≤20 ng/ml) with an expected stay in the medical
ICU of more than 48 hours were randomly assigned to
receive either 540,000 IU of vitamin D3 (which equalled
three bottles of a commercially available vitamin D pre-
paration in Austria: Oleovit D3
® solution; 400 IU vita-
min D3/drop) dissolved in 45 ml of herbal oil ("VITD”
group) or herbal oil only (placebo group, “PBO” group).
The study medication was prepared, labelled and rando-
mized by a pharmacist and physician not involved in the
trial. The randomization was performed with sealed
envelopes and all aspects of the trial were performed in
a double-blind fashion. Exclusion criteria included mori-
bund patients expected to die within 24 hours, hypercal-
cemia, ileus, pregnancy, and a history of kidney stones,
sarcoidosis or tuberculosis. Most patients received the
study medication via a nasogastric feeding tube, while
two patients in each group were able to take it orally.
The institutional ethical committee approved the trial
before commencement (protocol number: 20-366 ex 08/
09; EudraCT 2009-012080-34, DRKS00000750). Patients
able to follow study protocol gave informed consent in
written form, while mechanically ventilated patients were
asked for their approval after regaining consciousness.
25(OH)D was measured by ELISA (Immunodiagnostic
Systems, Boldon, UK). On weekdays, 25(OH)D analyses
in our institution were performed on a daily basis. 1,25-
(OH)2D was analysed with ELISA (Immunodiagnostic
Systems, Boldon, UK). Serum electrolytes as well as urin-
ary creatinine and electrolytes were measured on a Roche
Modular (Roche Diagnostics, Mannheim, Germany).
Parathyroid hormone (PTH) was analyzed by electroche-
miluminescence immunoassay (Elecsys 2010, Roche
Diagnostics, Mannheim, Germany). Serum triglycerides
were determined enzymatically with the GPO-PAP
method (Roche Diagnostics, Mannheim, Germany).
N-terminal prohormone brain natriuretic peptide (NT-
proBNP) was measured by electrochemiluminescence
(Elecsys 2010, Roche Diagnostics, Mannheim, Germany).
The active study participation for each patient lasted
seven days with an optional follow up at 28 days in case
patients were still residing within the hospital. The pri-
mary endpoint was the percentage of patients who
reached 25(OH)D levels of 30 ng/ml or above on day 7.
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clinical parameters related to vitamin D and mineral
metabolism (i.e. 1,25(OH)2D, serum PTH levels, serum
electrolytes, urinary calcium/creatinine ratio, and
NT-proBNP levels), length of hospital and ICU stay,
duration of mechanical ventilation and catecholamine
support as well as hospital mortality.
Statistical analysis
Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago,
IL, USA) and are expressed as mean ± standard devia-
tion or median (interquartile range) as appropriate.
Between-group comparisons were carried out using
Mann-Whitney-U test and chi squared-test where
appropriate. Unifactorial repeated measures analysis of
variance was used to analyze changes in blood and urin-
ary parameters.
Results
Out of 25 patients enrolled we could obtain results from
20 at day 7 (10 in each group). The 25(OH)D level in
the VITD group was 13.1 ± 2.0 ng/ml (mean ± standard
deviation) on day 0, 35.1 ± 15.2 ng/ml on day 3 and
38.2 ± 16.5 ng/ml on day 7 (respective interquartile
ranges 3.5, 18.5, and 21.5), while in the PBO group it
was 14.1 ± 3.7 ng/ml on day 0, 14.5 ± 4.6 ng/ml on day
3 and 13.7 ± 4.2 ng/ml on day 7 (respective interquartile
ranges 7.2, 6.2, and 7.5).
Clinical characteristics of the participants are given in
Table 1. Biochemical changes during the follow-up per-
iod are shown in Table 2. Already on day 1, 25(OH)D
was significantly higher in the intervention group
(Figure 1). Eight out of 10 patients showed a normaliza-
tion of 25(OH)D levels (≥30 ng/ml), and the highest
level achieved was 64 ng/ml on day 3.
Two patients in the VITD group demonstrated either
a small (7 ng/ml) or no (1 ng/ml) increase in 25(OH)D
levels. In one patient, this may be attributable to gastro-
intestinal dysfunction after hypoxia related to near-
drowning and resuscitation, and in the other to a history
of sclerodermiform gastrointestinal graft-versus-host dis-
ease after allogeneic stem cell transplantation. Individual
patient data are given in Table 3.
Total serum calcium and ionized calcium increased
significantly in both groups, whereas 1,25(OH)2D levels
did so in the VITD group only. The proportion of
patients with normocalcemia on day 3 and 7 (ionized
calcium ≥1.15 mmol/l) was not significantly different
between both groups. Serum PTH levels had declined
although not significantly in both groups at day 7. In
this pilot study there were no differences in clinical out-
come variables such as duration of mechanical ventila-
tion, vasopressor dependency, or mortality between the
two groups (Table 1). Interestingly, hospital mortality in
patients who became normocalcemic on day 3 (ionized
calcium ≥1.15 mmol/l) compared with those who
Table 1 Clinical characteristics at baseline and secondary clinical outcomes of the two groups
Placebo
(n = 13)
Vitamin D
(n = 12)
P value
Baseline characteristics
Male - n (%) 10 (77) 9 (75) 0.91
Age (years) 64.1 ± 16.4 61.1 ± 16.7 0.65
Body mass Index (kg/m
2) 29.3 ± 8.5 28.7 ± 9.7 0.87
SAPS II (ICU admission) 38.3 ± 22.3 33.2 ± 12.2 0.47
TISS (study start) 38.0 ± 7.2 30.2 ± 7.1 0.08
Renal replacement therapy - n (%) 3 (23) 1 (8) 0.31
Diagnostic category infectious (4) infectious (6)
cardiovascular (4) cardiovascular (3)
neurologic (4) neurologic (1) -
gastrointestinal (1) gastrointestinal (0)
other (0) other (2)
Mechanical ventilation - n (%) 11 (85) 10 (83) 0.93
Vasopressor therapy - n (%) 12 (92) 8 (67) 0.10
Outcome variables
Mechanical ventilation - duration (hours) 163 (91-541) 229 (82-366) 0.88
Vasopressor therapy - duration (hours) 146 (48-351) 65 (42-299) 0.56
Hospital stay, days (from study start) 15 (8-38) 16 (8-32) 0.97
ICU stay, days (from study start) 6 (3-23) 10 (5-21) 0.54
Hospital mortality - n (%) 6 (46) 6 (50) 0.84
Continuous data are presented as means (standard deviation) or median (interquartile range), categorical data are shown in total numbers (percentages).
SAPS, simplified acute physiology score; TISS 28, Therapeutic Intervention Scoring System.
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versus 55%) although this difference did not reach statis-
tical significance.
Discussion
In this pilot study an enteral ultra-high dose of 540,000
IU of vitamin D3 given once to vitamin D-deficient
patients was able to rapidly normalize 25(OH)D levels
in most patients in a medical ICU setting. Conversely,
routine replacement with daily doses of 200 IU of chole-
calciferol in the PBO group did not have any effect on
25(OH)D levels. The highest achieved 25(OH)D level in
the VITD group was 64 ng/ml and far away from levels
thought to be indicative of toxicity (>200 ng/ml) [22].
However, the individual maximal rise following applica-
tion of this single dose of vitamin D3 was variable, ran-
ging from 1 to 47 ng/ml. In other (non-critically ill)
populations the effect of a large dose of vitamin D
yielded somewhat comparable or slightly higher 25(OH)
D levels one week after administration [24,26].
The progressive increase in 25(OH)D levels may not
only be explained by initial differences in intestinal
absorption of vitamin D3, but also by limited capacity of
the vitamin D binding protein transport system, or that
of the liver to hydroxylate the precursor. Moreover,
there may be interindividual differences applying to sto-
rage effects, whereby cholecalciferol is taken up or
released by adipose and muscle tissues. However, most
of the vitamin D that enters the body is catabolized and
excreted without ever being stored in tissues, and with-
out ever becoming 25(OH)D [27]. We thus cannot
exclude that either a change towards smaller dosages or
more frequent dosing intervals may also have yielded
the desired effects and normalized 25(OH)D levels.
Our study provides novel information on how vitamin
D replacement may correct vitamin D deficiency. Of
interest in this study is also the plasma kinetics of 1,25
(OH)2D that in this small patient sample indicated pro-
gressive and at day 3 almost three-fold increase above
baseline levels that seemed to rapidly decline thereafter.
As serum PTH and total calcium levels, which both mod-
ulate CYP27B1 activity, remained unchanged during that
period, it seems that this transient rise in 1,25(OH)2D
was mainly attributable to the boost of suddenly available
2 5 ( O H ) Ds u b s t r a t e .Ap l a u s i b l er e a s o nf o rt h es u b s e -
quent decrease in 1,25(OH)2D levels following day 3 may
be the induction of CYP24 hydroxylase gene that shifts
25(OH)D more towards the production of inactive 24,25
(OH)2D thus limiting the rise of 1,25(OH)2D levels.
Table 2 Biochemical changes during the seven-day
observational period
Day 0 Day 1 Day 2 Day 3 Day 7
25(OH)D (ng/ml)
Placebo group 14.1 15.3* 15.0* 14.5* 13.7*
Vitamin D group 13.1 20.5*
§ 33.1*
§ 35.1*
§ 38.2*
§
1,25(OH)2D (pmol/l)
Placebo group 50.6 36.3* 36.6 47.1 67.0
Vitamin D group 68.6 89.5*
§ 175.2*
§ 170.8*
§ 114.2
PTH (pg/ml)
Placebo group 91.3 72.0 79.0 75.7 71.7
Vitamin D group 73.7 65.1 77.3 100.4 52.0
Ionized serum calcium (mmol/l)
Placebo group 1.03
- - 1.05 1.14
§
Vitamin D group 1.09
- - 1.11 1.14
§
Total serum calcium (mmol/l)
Placebo group 2.03 2.02 1.98 2.02 2.13
§
Vitamin D group 2.05 2.05 2.09 2.12 2.20
§
Serum phosphorus (mmol/l)
Placebo group 1.57* 1.34 1.49* 1.51* 1.22
Vitamin D group 1.01* 1.20 1.08* 1.07* 1.17
Triglycerides (mg/dl)
Placebo group 111 126 - - 116
Vitamin D group 180 175 - - 178
NTproBNP (pg/ml)
Placebo group 2100 - - - 2120
Vitamin D group 3089 - - - 3117
Urinary calcium/creatinine ratio (mmol/mmol)
Placebo group 0.38 0.24 0.14 0.15 0.41
Vitamin D group 0.38 0.19 0.27 0.28 0.27
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D,
NTproBNP, N-terminal prohormone brain natriuretic peptide; PTH, parathyroid
hormone.
§, P < 0.05 for intra-group comparisons (calculated in relation to baseline
values) and *, P < 0.05 for between-group comparisons.
Figure 1 Mean 25-hydroxyvitamin D levels (±SEM) after a
single enteral dose of 540,000 IU vitamin D3 or placebo in
vitamin D deficient patients at a medical ICU. The numbers
given below the study days refer to the number of patients per
group.
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one-week observation period (without a respective
change in serum protein) and likely represent the conse-
quence of acute immobilization on bone turnover
dynamics. It is of note that despite the marked increases
in serum 25(OH)D and 1,25(OH)2D as well as serum cal-
cium levels there was no clear-cut suppression of PTH
secretion in the VITD group and only a tendency for
lower levels. We speculate that these data may be indica-
tive of a change in calcium responsiveness of the para-
thyroid gland in critically ill patients. Hypercalcemia was
not encountered at any time-point in this patient setting.
Despite the high fat content of the study medication, tri-
glyceride levels did not change significantly in either
group, neither did NTproBNP serum levels, as opposed
to recent results in older patients with heart failure [28].
The most important limitation of this pilot study is its
size. The results may not be applicable to every patient
group encountered in the ICU. Not surprisingly, we did
not find any differences in clinical outcome parameters;
however, the sample size and its statistical power did not
allow for such analysis. A larger trial addressing these
issues is currently being performed at our institution.
Conclusions
The administration of high-dose vitamin D continues to
be a promising and inexpensive intervention in vitamin
D-deficient critically ill patients that has a low-risk profile
and a broad therapeutic window. Further trials are
needed to confirm that the dosing scheme proposed by
the results of this study is indeed reasonable and most
importantly, that normalization of 25(OH)D status is also
related to improvement in clinical outcome parameters.
Key messages
￿ Vitamin D deficiency is highly prevalent and is
linked to increased morbidity and mortality in the
general population.
￿ Vitamin D plays a crucial role in calcium homeos-
tasis besides other skeletal and non-skeletal effects;
it has an excellent safety profile and likely a broad
therapeutic window.
￿ T h es c a r c ea v a i l a b l ed a t as u g g e s tt h a tv i t a m i nD
deficiency affects the majority of patients in the ICU
despite vitamin D supplementation in enteral and
parenteral nutrition.
￿ This pilot study is the first randomized controlled
trial that investigates short-term effects of high-dose
vitamin D in a limited number of critically ill
patients.
￿ Further research is needed to study whether vita-
min D deficiency is an independent risk factor for
critically ill patients and if correction leads to clinical
benefits.
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